Prelude Therapeutics (PRLD) Retained Earnings (2019 - 2026)

Prelude Therapeutics has disclosed Retained Earnings across 8 years of filings, most recently posting -$693.4 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$693.4 million, down 12.64% year-over-year; the trailing twelve-month figure through Mar 2026 was -$693.4 million (down 12.64% YoY), and the FY2025 annual result was -$683.1 million, down 1951702.86% from the prior year.
• Retained Earnings came in at -$693.4 million for Q1 2026 at Prelude Therapeutics, down from -$683.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $35000.0 in Q4 2024 to a low of -$693.4 million in Q1 2026.
• The 5-year median for Retained Earnings is -$362.3 million (2023), against an average of -$325.8 million.
• Across the five-year window, Retained Earnings jumped 100.01% in 2024 and tumbled 1951702.86% in 2025, its largest moves.
• Prelude Therapeutics' Retained Earnings stood at -$334.6 million in 2022, then sank by 36.42% to -$456.4 million in 2023, then surged by 100.01% to $35000.0 in 2024, then sank by 1951702.86% to -$683.1 million in 2025, then dropped by 1.51% to -$693.4 million in 2026.
• The last three Retained Earnings figures came in at -$693.4 million (Q1 2026), -$683.1 million (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.